The Latest Cardiac and Vascular News
– Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) – – Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd American Society of Hematology […]
– Acceleron expects to report approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated […]
– Highlighted ongoing and planned trials in rare pulmonary diseases and presented vision and strategy for long-term growth at June R&D Day – – Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial […]
– Treatment with sotatercept in the ongoing SPECTRA Phase 2 trial was associated with improvements in resting and exercise hemodynamics at week 24 – – Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and […]
– PULSAR Phase 2 trial results published in New England Journal of Medicine – – Updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept in patients with pulmonary arterial hypertension (PAH) to be presented at the American Thoracic […]
– Acceleron expects to report approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated […]
– Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions – – STELLAR Phase 3 trial initiated with sotatercept in […]
– Acceleron expects to report approximately $23.0 million in royalty revenue for Q4 2020 from approximately $115 million in net sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – – Acceleron expects to report approximately $54.8 million in royalty […]
– Sotatercept received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) in PAH in 2019 – – In the spring of 2020, sotatercept received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the […]
– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR trial received AHA’s “Cardiopulmonary Best Abstract” Award – […]
